Identifying molecular markers for tumor recurrence is critical in successfully selecting patients with stage III colon cancer who are more likely to benefit from adjuvant chemotherapy. The present study analyzed a subset of 10 polymorphisms within eight genes involved in the tumor angiogenesis pathway and their impact on prognosis in stage III colon cancer patients treated with adjuvant chemotherapy.
Division of Medical Oncology, University of SouthernCalifornia, Sharon A Carpenter Laboratory, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
